ClearBridge Investments’s ImmunityBio IBRX Stock Holding History

ClearBridge Investments’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-2,000	Closed	-$7K	–	1187
2017 Q1	$7K	Hold	2,000	–	–	﹤0.01%	1080
2016 Q4	$11K	Hold	2,000	–	–	﹤0.01%	1068
2016 Q3	$16K	Hold	2,000	–	–	﹤0.01%	959
2016 Q2	$12K	Hold	2,000	–	–	﹤0.01%	978
2016 Q1	$16K	Hold	2,000	–	–	﹤0.01%	946
2015 Q4	$35K	Hold	2,000	–	–	﹤0.01%	941
2015 Q3	$23K	Buy	+2,000	New	+$43.6K	﹤0.01%	1016

Other funds holding IBRX

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

VIA

Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return

ClearBridge Investments's IBRX Position: Q2 2017 in Review

ClearBridge Investments sold out of ImmunityBio (IBRX) in Q2 2017, closing a stake of 2,000 shares — an estimated $7K sold.

ClearBridge Investments first reported a position in IBRX in Q3 2015 and held it in 7 quarters. The position peaked at $35K in Q4 2015. 58 funds tracked by Wall St. Rank hold IBRX as of Q2 2017.

ClearBridge Investments reported no remaining ImmunityBio position as of Q2 2017 after selling out during the quarter.
ClearBridge Investments sold 2,000 ImmunityBio shares in Q2 2017, an estimated $7K.
ClearBridge Investments first reported a position in ImmunityBio in Q3 2015 and held it in 7 quarters.
ClearBridge Investments's ImmunityBio position peaked at $35K in Q4 2015.
58 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2017.

Based on ClearBridge Investments's 13F filing for Q2 2017, filed 14 Aug 2017.